Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 6 clients • 8 examiners • 8 art units • 0 of 8 (0%) have an AI response strategy ready
Prismatic Law Group, PLLC focuses its practice on the Biotechnology & Pharmaceuticals technology area, where it has managed 176 career applications. The firm has achieved a resolved allowance rate of 77.19 in this field. On average, the firm navigates 3.68 office actions per allowance during the prosecution process.
There are currently 8 pending office actions under the firm's management. This active docket is part of a history involving 176 career applications. The 77.19 resolved allowance rate reflects the firm's effectiveness in the Biotechnology & Pharmaceuticals sector.
The average of 3.68 office actions per allowance provides insight into the typical duration of negotiations with patent examiners. With 8 pending office actions currently active, the firm remains engaged in securing intellectual property rights within its technical domain.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (25%) |
| §103 only | 2 (25%) |
| §112 only | 1 (12%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VALENROD, YEVGENY | 1 | 72.5% | +25.1% |
| DONOGHUE, BRITTNEY ERIN | 1 | 58.7% | +47.4% |
| MELCHIOR, JAMES RYLAND | 1 | 62.2% | +39.5% |
| MOSELEY II, NELSON B | 1 | 67.9% | +41.7% |
| WEDDINGTON, KEVIN E | 1 | 75.3% | +9.8% |
| LEVERETT, MARY CHANG | 1 | 59.4% | +23.5% |
| MAHLUM, JONATHAN DAVIS | 1 | 50.0% | +23.3% |
| MIANO, JOSEPH PAUL | 1 | 35.7% | +63.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18184657 | TREATMENT OF AUTOIMMUNE SKIN DISEASE | WEDDINGTON, KEVIN E | 182d overdue |
| 17995525 | METHOD FOR IDENTIFYING SIGNATURES FOR PREDICTING TREATMENT RESPONSE | LEVERETT, MARY CHANG | 30d |
| 18317385 | DUAL TARGETING | MOSELEY II, NELSON B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906184 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) FOR DEGRADATION OF AURORA A-KINASE | MAHLUM, JONATHAN DAVIS | 80d overdue |
| 17995525 | METHOD FOR IDENTIFYING SIGNATURES FOR PREDICTING TREATMENT RESPONSE | LEVERETT, MARY CHANG | 30d |
| 18835823 | DHODH INHIBITOR POLYMORPH | VALENROD, YEVGENY | — |
| 18258939 | ANTIBODY VARIABLE DOMAINS THAT BIND IL-4R | DONOGHUE, BRITTNEY ERIN | — |
| 18258957 | ANTIBODY VARIABLE DOMAINS AND ANTIBODIES HAVING DECREASED IMMUNOGENICITY | MELCHIOR, JAMES RYLAND | — |
| 18317385 | DUAL TARGETING | MOSELEY II, NELSON B | — |
| 16621741 | NOVEL METHODS FOR THE GENERATION AND USE OF HUMAN INDUCED NEURAL BORDER STEM CELLS | MIANO, JOSEPH PAUL | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Aslan Pharmaceuticals | 2 |
| Numab Therapeutics AG | 2 |
| Roche | 1 |
| UMC UTRECHT HOLDING B.V. | 1 |
| Julius-Maximilians-Universität Würzburg | 1 |
| Hi-Stem Ggmbh | 1 |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1675 | 1 |
| 1644 | 1 |
| 1642 | 1 |
| 1629 | 1 |
| 1687 | 1 |
| 1625 | 1 |
| 1631 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18835823 | DHODH INHIBITOR POLYMORPH | Aslan Pharmaceuticals Pte Ltd | VALENROD, YEVGENY | 1628 | §112 | Non-Final OA | — | Pending | Aug 05, 2024 |
| 18258939 | ANTIBODY VARIABLE DOMAINS THAT BIND IL-4R | Numab Therapeutics AG | DONOGHUE, BRITTNEY ERIN | 1675 | §112DP | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18258957 | ANTIBODY VARIABLE DOMAINS AND ANTIBODIES HAVING DECREASED IMMUNOGENICITY | Numab Therapeutics AG | MELCHIOR, JAMES RYLAND | 1644 | §112DPOther | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18317385 | DUAL TARGETING | Hoffmann-La Roche, Inc. | MOSELEY II, NELSON B | 1642 | §102§112 | Non-Final OA | — | Pending | May 15, 2023 |
| 18184657 | TREATMENT OF AUTOIMMUNE SKIN DISEASE | Aslan Pharmaceuticals Pte Ltd | WEDDINGTON, KEVIN E | 1629 | §101§102§103§112 | Non-Final OA | 182d overdue | Pending | Mar 16, 2023 |
| 17995525 | METHOD FOR IDENTIFYING SIGNATURES FOR PREDICTING TREATMENT RESPONSE | UMC Utrecht Holding B.V. | LEVERETT, MARY CHANG | 1687 | §101§103§112 | Non-Final OA | 30d | Pending | Oct 05, 2022 |
| 17906184 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) FOR DEGRADATION OF AURORA A-KINASE | Julius-Maximilians-Universitaet Wuerzburg | MAHLUM, JONATHAN DAVIS | 1625 | §103 | Final Rejection | 80d overdue | Pending | Sep 12, 2022 |
| 16621741 | NOVEL METHODS FOR THE GENERATION AND USE OF HUMAN INDUCED NEURAL BORDER STEM CELLS | Hi-Stem Ggmbh | MIANO, JOSEPH PAUL | 1631 | §103 | Non-Final OA | — | Pending | Dec 12, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial77.2% of resolved applications prosecuted by Prismatic Law Group, Pllc were allowed, across 176 applications in USPTO records.
3.68 office actions per allowed application on average.
8 pending office actions as of October 2026, for 6 clients, before 8 examiners in 8 art units.
